Big News: This American pharma company will invest more than $1 billion in India.

News Topical, Digital Desk : Big News: According to Reuters, American pharmaceutical company Eli Lilly has announced an investment of more than $1 billion in India. The company will strengthen its drug production capacity and supply network in the country in the coming years. Lilly is partnering with local pharmaceutical companies to increase the availability of key drugs used to treat obesity, diabetes, Alzheimer's, cancer, and autoimmune diseases.

India is a key hub for Eli Lilly.
Eli Lilly International President Patrik Jonsson stated that the company is making significant investments to expand production capacity globally, and India has become a key hub for this. Lilly currently does not have its own manufacturing facility in India, but it is working with several local companies on a contract manufacturing model. 

Manufacturing and Quality Center in India! The company stated that its new manufacturing and quality center in India will be established in Hyderabad, part of Eli Lilly's global network. This hub will oversee the existing contract manufacturing network in India and provide technical support. The company stated that recruitment for this new site will begin immediately, hiring engineers, chemists, analytical scientists, and quality experts. Lilly's move comes at a time when the US imposed a 100% tariff on imported patented drugs effective October 1st, prompting many global companies to expand production in India. The company recently announced plans to set up a new unit in Virginia, USA, with an investment of $5 billion, as part of its $27 billion global expansion plan. The obesity treatment market is growing rapidly in India following the launch of drugs like Mounjaro and Wegovy, and Eli Lilly is looking to strengthen its position in this segment.
 

Read More: Coforge Q2 Results: Company profits rise, dividend announced